Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Goodwill & Intangibles (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Goodwill & Intangibles for 16 consecutive years, with $9.7 million as the latest value for Q4 2025.

  • Quarterly Goodwill & Intangibles fell 64.01% to $9.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.7 million through Dec 2025, down 64.01% year-over-year, with the annual reading at $9.7 million for FY2025, 64.01% down from the prior year.
  • Goodwill & Intangibles for Q4 2025 was $9.7 million at Anika Therapeutics, down from $23.8 million in the prior quarter.
  • The five-year high for Goodwill & Intangibles was $120.9 million in Q2 2021, with the low at $8.3 million in Q3 2024.
  • Average Goodwill & Intangibles over 5 years is $68.6 million, with a median of $81.7 million recorded in 2022.
  • The sharpest move saw Goodwill & Intangibles plummeted 93.08% in 2024, then surged 188.12% in 2025.
  • Over 5 years, Goodwill & Intangibles stood at $90.2 million in 2021, then surged by 32.51% to $119.5 million in 2022, then plummeted by 77.06% to $27.4 million in 2023, then fell by 1.63% to $27.0 million in 2024, then tumbled by 64.01% to $9.7 million in 2025.
  • According to Business Quant data, Goodwill & Intangibles over the past three periods came in at $9.7 million, $23.8 million, and $9.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.